Aon launches cargo insurance coverage for COVID-19 vaccines | CDC panel defers vote on resuming J&J vaccine use | Report: EU may not renew AstraZeneca, J&J vaccine deals
Aon, in collaboration with other stakeholders, is offering a cargo insurance coverage program for COVID-19 vaccines that will use sensor data and analytics to manage risks. Aon said it would donate all revenues from the program to pandemic-related charities.
A panel of CDC advisers decided to postpone a vote on whether the US government should call for states to resume the use of Johnson & Johnson's single-dose COVID-19 vaccine, in order to gather more safety information. The vote could be delayed by at least a week as the panel investigates six rare blood clot incidents linked to the vaccine.
The European Commission reportedly will not renew its COVID-19 vaccine contracts with AstraZeneca and Johnson & Johnson when they expire at the end of the year, over concerns about blood clots and stalled deliveries, according to an Italian newspaper. The EU may rely more on the Pfizer/BioNTech and Moderna vaccines, the newspaper reported.
The World Health Organization said more than 87% of COVID-19 vaccine doses have gone to people in high-income countries. The WHO's COVAX program has begun dispersing COVID-19 vaccinations to 100 of the world's poorest countries and has delivered 40 million vaccine doses so far across six continents.
The FDA has released a guidance explaining how the agency plans to conduct remote interactive evaluations of pharmaceutical and biomedical research sites during the pandemic. The agency said it will consider the use of remote interactive evaluations for all of its drug inspection programs, and some of the tools that will be used during remote inspections include livestreaming video, teleconferencing and screen-sharing technologies.
Thermo Fisher said it had reached an agreement to buy clinical testing company PPD for $17.4 billion. PPD will become part of its laboratory products and services unit.
There are many unknowns when a new administration takes office in the US. This article outlines what risk managers should consider when operating in a new environment.
A roadmap to de-SPACing: A guide to successful de-SPAC transactions
2020 was the year of the Special Purpose Acquisition Company (SPAC) with more than 200 entities going public via SPAC last year alone. While the SPAC IPO boom continues, 2021 is also expected to be the year of the "de-SPAC". In this webinar replay, Aon and esteemed panelists discuss the SPAC target approach, share insights with real-world case studies, and de-mystify the de-SPACing process.
You don't paddle against the current, you paddle with it. And if you get good at it, you throw away the oars.
Kris Kristofferson, singer-songwriter, actor
About Aon Life Sciences Practice
Aon provides Life Sciences companies with end-to-end risk solutions, supporting organizations from the initial discovery phase to final product launch. The practice provides solutions across the Life Sciences for pharmaceutical manufacturers; generic and OTC pharmaceutical companies; biotechnology and biopharmaceutical companies; genomic and proteomic companies; drug delivery system; diagnostic substance companies; and medical device and equipment manufacturers.
Contact Aon
Aon Risk Solutions – Life Sciences
James Walters, Global Practice Leader
+1.215.255.1795 james.walters@aon.com www.aon.com
About Aon
Aon plc (NYSE:AON) is a leading global professional services firm providing a broad range of risk, retirement and health solutions. Our 50,000 colleagues in 120 countries empower results for clients by using proprietary data and analytics to deliver insights that reduce volatility and improve performance.
SmartBrief publishes more than 200 free industry newsletters - Browse our portfolio